.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Baxter
Johnson and Johnson
Novartis
Cipla
Queensland Health
Covington
Accenture
Deloitte
Federal Trade Commission
Chubb

Generated: September 23, 2017

DrugPatentWatch Database Preview

Details for Patent: ► Subscribe

« Back to Dashboard

Details for Patent: ► Subscribe

Title:GH secretagogues and uses thereof
Abstract: The invention relates to use of a GH secretagogue (e.g. GRF or an analog thereof) for (1) altering a lipid parameter in a subject; (2) altering a body composition parameter in a subject, (3) treating a condition characterized by deficient or decreased bone formation in a subject (4) improving daytime vigilance and/or cognitive function in a subject, (5) improving a metabolic condition in a subject, (6) improving anabolism in a catabolic condition in a subject, and/or (7) improving and/or reconstituting immune function in a subject.
Inventor(s): Abribat; Thierry (St-Foy-les-Lyon, FR), De Villers; Andre (Outremont, CA), Chapdelaine; Alcide (Ile des Soeurs, CA), Allas; Soraya (Iles des Soeurs, CA), Gravel; Denis (Saint-Lambert, CA)
Assignee: Theratechnologies Inc. (Montreal, Quebec, CA)
Filing Date:Oct 23, 2007
Application Number:11/877,395
Claims:1. A method of treating HIV-related lipodystrophy in a subject without significantly impairing glucose control, said method comprising administering to said subject (hexenoyl trans-3)hGRF(1-44)NH.sub.2 (SEQ ID NO: 7) to treat said HIV-related lipodystrophy without significantly impairing glucose control.

2. The method of claim 1, wherein said subject is receiving antiviral therapy.

3. The method of claim 1, wherein said (hexenoyl trans-3)hGRF(1-44)NH.sub.2 (SEQ ID NO: 7) is administered at a dose selected from the group consisting of about 1 mg and about 2 mg.

4. The method of claim 1, wherein said (hexenoyl trans-3)hGRF(1-44)NH.sub.2 (SEQ ID NO: 7) is administered by a route selected from the group consisting of intravenous, oral, transdermal, subcutaneous, mucosal, intramuscular, intranasal, intrapulmonary, parenteral, intrarectal and topical.

5. The method of claim 4, wherein said (hexenoyl trans-3)hGRF(1-44)NH.sub.2 (SEQ ID NO: 7) is administered by a subcutaneous route.

6. The method of claim 3, wherein said (hexenoyl trans-3)hGRF(1-44)NH.sub.2 (SEQ ID NO: 7) is administered at a dose of about 2 mg.

7. The method of claim 5, wherein said (hexenoyl trans-3)hGRF(1-44)NH.sub.2 (SEQ ID NO: 7) is administered at a dose selected from the group consisting of about 1 mg and about 2 mg.

8. The method of claim 7, wherein said (hexenoyl trans-3)hGRF(1-44)NH.sub.2 (SEQ ID NO: 7) is administered at a dose of about 2 mg.

9. The method of claim 1, wherein said treating HIV-related lipodystrophy comprises treating visceral fat accumulation.

10. The method of claim 2, wherein said treating HIV-related lipodystrophy comprises treating visceral fat accumulation.

11. The method of claim 3, wherein said treating HIV-related lipodystrophy comprises treating visceral fat accumulation.

12. The method of claim 4, wherein said treating HIV-related lipodystrophy comprises treating visceral fat accumulation.

13. The method of claim 5, wherein said treating HIV-related lipodystrophy comprises treating visceral fat accumulation.

14. The method of claim 6, wherein said treating HIV-related lipodystrophy comprises treating visceral fat accumulation.

15. The method of claim 7, wherein said treating HIV-related lipodystrophy comprises treating visceral fat accumulation.

16. The method of claim 8, wherein said treating HIV-related lipodystrophy comprises treating visceral fat accumulation.

17. The method of claim 1, wherein said subject further suffers from type II diabetes or glucose intolerance.

18. The method of claim 2, wherein said subject further suffers from type II diabetes or glucose intolerance.

19. The method of claim 3, wherein said subject further suffers from type II diabetes or glucose intolerance.

20. The method of claim 4, wherein said subject further suffers from type II diabetes or glucose intolerance.

21. The method of claim 5, wherein said subject further suffers from type II diabetes or glucose intolerance.

22. The method of claim 6, wherein said subject further suffers from type II diabetes or glucose intolerance.

23. The method of claim 7, wherein said subject further suffers from type II diabetes or glucose intolerance.

24. The method of claim 8, wherein said subject further suffers from type II diabetes or glucose intolerance.

25. The method of claim 9, wherein said subject further suffers from type II diabetes or glucose intolerance.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Express Scripts
Harvard Business School
Cerilliant
AstraZeneca
Healthtrust
Deloitte
Citi
Covington
Farmers Insurance
Daiichi Sankyo

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot